Drug Profile
Research programme: 5-lipoxygenase inhibitors - Naegis Pharmaceuticals
Alternative Names: N0550Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Naegis Pharmaceuticals
- Class Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Asthma in Canada
- 31 Dec 2010 Early research in Asthma in Canada (unspecified route)